Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein
Int J Cancer
.
2021 Aug 1;149(3):741-742.
doi: 10.1002/ijc.33572.
Epub 2021 Mar 24.
Authors
Elie Naddaf
1
,
Taxiarchis Kourelis
2
Affiliations
1
Department of Neurology, Division of Neuromuscular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
2
Department of Internal medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
PMID:
33742684
DOI:
10.1002/ijc.33572
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal
Humans
Myopathies, Nemaline* / drug therapy
Substances
Antibodies, Monoclonal